Population net benefit of prostate MRI with high spatiotemporal resolution contrast‐enhanced imaging: A decision curve analysis

Abstract

Background The value of dynamic contrast‐enhanced (DCE) sequences in prostate MRI compared with noncontrast MRI is controversial. Purpose To evaluate the population net benefit of risk stratification using DCE‐MRI for detection of high‐grade prostate cancer (HGPCA), with or without high spatiotemporal resolution DCE imaging. Study Type Decision curve analysis. Population Previously published patient studies on MRI for HGPCA detection, one using DCE with golden‐angle radial sparse parallel (GRASP) images and the other using standard DCE‐MRI. Field Strength/Sequence GRASP or standard DCE‐MRI at 3 T. Assessment Each study reported the proportion of lesions with HGPCA in each Prostate Imaging Reporting and Data System version 2 (PI‐RADS v2) category (1–5), before and after reclassification of peripheral zone lesions from PI‐RADS 3–4 based on contrast‐enhanced images. This additional risk stratifying information was translated to population net benefit, when biopsy was hypothetically performed for: all lesions, no lesions, PI‐RADS ≥3 (using NC‐MRI), and PI‐RADS ≥4 on DCE. Statistical Tests Decision curve analysis was performed for both GRASP and standard DCE‐MRI data, translating the avoidance of unnecessary biopsies and detection of HGPCA to population net benefit. We standardized net benefit values for HGPCA prevalence and graphically summarized the comparative net benefit of biopsy strategies. Results For a clinically relevant range of risk thresholds for HGPCA (>11%), GRASP DCE‐MRI with biopsy of PI‐RADS ≥4 lesions provided the highest net benefit, while biopsy of PI‐RADS ≥3 lesions provided highest net benefit at low personal risk thresholds (2–11%). In the same range of risk thresholds using standard DCE‐MRI, the optimal strategy was biopsy for all lesions (0–15% risk threshold) or PI‐RADS ≥3 on NC‐MRI (16–33% risk threshold). Data Conclusion GRASP DCE‐MRI may potentially enable biopsy of PI‐RADS ≥4 lesions, providing relatively preserved detection of HGPCA and avoidance of unnecessary biopsies compared with biopsy of all PI‐RADS ≥3 lesions. J. Magn. Reson. Imaging 2019;49:1400–1408.

Development and validation of a nomogram to predict the mortality risk in elderly patients with ARF

“…However, evaluating the clinical usefulness of our nomogram depends on how much it benefits the patient, not just its popularization ( Huang et al, 2016 ). DCA is a novel method that has been widely used in the evaluation of clinical research effectiveness ( Hijazi et al, 2016 ; Prabhu et al, 2019 ; Talluri & Shete, 2016 ). It offers insight into clinical consequences on the basis of threshold probability, from which the net benefit could be derived ( Balachandran et al, 2015 ).…”

Development and Validation of a Diagnostic Nomogram to Predict COVID-19 Pneumonia

“…However, to evaluate its clinical usefulness, it depends on how much it benefits the patient, not just its popularization 29 . DCA is an novel method 30,31 , it offers insight into clinical consequences on the basis of threshold probability, from which the net benefit could be derived 32 . The DCA showed that if we choose to diagnose COVID-19 pneumonia with a 60% threshold probability, 40 out of every 100 people will benefit.…”

Development and Validation of a Diagnostic Nomogram to Predict COVID-19 Pneumonia

“…However, to evaluate its clinical usefulness, it depends on how much it benefits the patient, not just its popularization [29]. DCA is an novel method [30,31], it offers insight into clinical consequences on the basis of threshold probability, from which the net benefit could be derived [32]. The DCA showed that if we choose to diagnose COVID-19 pneumonia with a 60% threshold probability, 40 out of every 13 100 people will benefit.…”